Last edition
News about "LYTENAVA "
Outlook Therapeutics Updates FDA Review of ONS-5010/LYTENAVA for Wet AMD
Outlook Therapeutics has provided an update on the U.S. Food and Drug Administration’s review of its resubmitted Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the treatment of wet age-related macular degeneration, following the FDA’s issuance of a Complete Response Letter (CRL).
LYTENAVA | 01/01/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members